ACADL and hepatocellular carcinoma: HCC organoids with high ACADL (NO.33 and NO.83) and low ACADL (NO.129 and NO.187) expression were treated with YAP inhibitor verteporfin, that pharmacologically disrupts TEAD-YAP interactions13.